"Febrile Neutropenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Fever accompanied by a significant reduction in the number of NEUTROPHILS.
| Descriptor ID |
D064147
|
| MeSH Number(s) |
C15.378.553.546.184.564.750
|
| Concept/Terms |
Febrile Neutropenia- Febrile Neutropenia
- Febrile Neutropenias
- Neutropenia, Febrile
- Neutropenias, Febrile
|
Below are MeSH descriptors whose meaning is more general than "Febrile Neutropenia".
Below are MeSH descriptors whose meaning is more specific than "Febrile Neutropenia".
This graph shows the total number of publications written about "Febrile Neutropenia" by people in this website by year, and whether "Febrile Neutropenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 4 | 5 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 4 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 2 | 5 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Febrile Neutropenia" by people in Profiles.
-
A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. J Antimicrob Chemother. 2024 Oct 01; 79(10):2543-2553.
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399.
-
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan; 10(1):e46-e58.
-
The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: A useful alternative to the multinational association for supportive care in cancer score. Cancer Med. 2021 12; 10(23):8475-8482.
-
Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol. 2021 Mar; 14(3):295-313.
-
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021 02 01; 96(2):208-217.
-
Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99.
-
In Reply. Oncologist. 2020 08; 25(8):e1252-e1253.
-
Impact of cardiovascular comorbidities on inpatient mortality in patients hospitalized with neutropenic fever. Support Care Cancer. 2021 Jan; 29(1):509-513.
-
Oncologic emergencies in the emergency medicine residency curriculum: A national survey. Am J Emerg Med. 2020 11; 38(11):2477-2481.